Guggenheim analyst Etzer Darout started Zealand Pharma (ZEAL) with a Buy rating, identifying the company and MyoKardia (MYOK) as "diamonds in the rough" that are focused on therapies for cardiovascular and metabolic disorders and targeting therapeutic segments where patients are more homogenous and/or targets are validated. He sees Zealand's major near-term driver being gleplagutide's pivotal data in patients with short bowel syndrome, due in the second half of 2020. He has a price target of DKK 235 on the local shares of ZEAL-DK, noting that Guggenheim is terminating coverage of the ADR shares of Zealand.